A Study of CS-3150 to Evaluate Efficacy and Safety in Patients with Primary Aldosteronism
Phase of Trial: Phase III
Latest Information Update: 17 Aug 2017
At a glance
- Drugs Esaxerenone (Primary)
- Indications Hyperaldosteronism
- Focus Registrational; Therapeutic Use
- Sponsors Daiichi Sankyo Company
- 10 Aug 2017 Status changed from active, no longer recruiting to completed.
- 15 May 2017 Status changed from recruiting to active, no longer recruiting.
- 07 Oct 2016 Status changed from not yet recruiting to recruiting.